Literature DB >> 1384050

Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro.

C F Barbas1, E Björling, F Chiodi, N Dunlop, D Cababa, T M Jones, S L Zebedee, M A Persson, P L Nara, E Norrby.   

Abstract

A panel of 20 recombinant Fab fragments reactive with the surface glycoprotein gp120 of human type 1 immunodeficiency virus (HIV-1) were examined for their ability to neutralize MN and IIIB strains of the virus. Neutralization was determined as the ability of the Fab fragments to inhibit infection as measured in both a p24 ELISA and a syncytium-formation assay. One group of closely sequence-related Fab fragments was found to neutralize virus in both assays with a 50% neutralization titer at approximately 1 micrograms/ml. Another Fab neutralized in the p24 ELISA but not in the syncytium assay. The other Fab fragments showed weak or no neutralizing ability. The results imply that virion aggregation or crosslinking of gp120 molecules on the virion surface is not an absolute requirement for HIV-1 neutralization. Further, all of the Fab fragments were shown to be competitive with soluble CD4 for binding to gp120 and yet few neutralized the virus effectively, implying that the mechanism of neutralization in this case may not involve receptor blocking. The observation of a preponderance of high-affinity Fab fragments with poor or no neutralizing ability could have implications for vaccine strategies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384050      PMCID: PMC50122          DOI: 10.1073/pnas.89.19.9339

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  Insights into neutralization of animal viruses gained from study of influenza virus.

Authors:  M C Outlaw; N J Dimmock
Journal:  Epidemiol Infect       Date:  1991-04       Impact factor: 2.451

2.  Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.

Authors:  C Y Kang; P Nara; S Chamat; V Caralli; T Ryskamp; N Haigwood; R Newman; H Köhler
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

3.  Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries.

Authors:  A S Kang; T M Jones; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

4.  Assembly of combinatorial antibody libraries on phage surfaces: the gene III site.

Authors:  C F Barbas; A S Kang; R A Lerner; S J Benkovic
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

5.  A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity.

Authors:  S A Tilley; W J Honnen; M E Racho; M Hilgartner; A Pinter
Journal:  Res Virol       Date:  1991 Jul-Aug

6.  An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.

Authors:  M R Posner; T Hideshima; T Cannon; M Mukherjee; K H Mayer; R A Byrn
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

7.  A predominant group-specific neutralizing epitope of human immunodeficiency virus type 1 maps to residues 342 to 511 of the envelope glycoprotein gp120.

Authors:  I Berkower; D Murphy; C C Smith; G E Smith
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

8.  Human combinatorial antibody libraries to hepatitis B surface antigen.

Authors:  S L Zebedee; C F Barbas; Y L Hom; R H Caothien; R Graff; J DeGraw; J Pyati; R LaPolla; D R Burton; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

9.  Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody.

Authors:  P L Nara; W C Hatch; N M Dunlop; W G Robey; L O Arthur; M A Gonda; P J Fischinger
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

10.  HIV requires multiple gp120 molecules for CD4-mediated infection.

Authors:  S P Layne; M J Merges; M Dembo; J L Spouge; P L Nara
Journal:  Nature       Date:  1990-07-19       Impact factor: 49.962

View more
  114 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

2.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  A binary plasmid system for shuffling combinatorial antibody libraries.

Authors:  T A Collet; P Roben; R O'Kennedy; C F Barbas; D R Burton; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

4.  Isolation of human monoclonal antibodies that neutralize human rotavirus.

Authors:  Kyoko Higo-Moriguchi; Yasushi Akahori; Yoshitaka Iba; Yoshikazu Kurosawa; Koki Taniguchi
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

Review 5.  Accessing the human repertoire for broadly neutralizing HIV antibodies.

Authors:  Philip W Hammond
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

6.  Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies.

Authors:  Sanchari Bhattacharyya; Roshan Elizabeth Rajan; Yalla Swarupa; Ujjwal Rathore; Anjali Verma; Ranga Udaykumar; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

7.  Biomarker discovery and clinical proteomics.

Authors:  Jerzy Silberring; Pawel Ciborowski
Journal:  Trends Analyt Chem       Date:  2010-02-01       Impact factor: 12.296

8.  Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries.

Authors:  R A Williamson; R Burioni; P P Sanna; L J Partridge; C F Barbas; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

9.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Elucidating the Basis for Permissivity of the MT-4 T-Cell Line to Replication of an HIV-1 Mutant Lacking the gp41 Cytoplasmic Tail.

Authors:  Melissa V Fernandez; Huxley K Hoffman; Nairi Pezeshkian; Philip R Tedbury; Schuyler B van Engelenburg; Eric O Freed
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.